Glycine

Glycine is the simplest amino acid and is studied across an unusually wide range of indications because it serves multiple distinct physiological roles: inhibitory neurotransmitter in the spinal cord and brainstem, co-agonist at brain NMDA glutamate receptors, building block for collagen and creatine, and a one-carbon-metabolism donor. The supplement literature covers sleep quality, schizophrenia treatment (as an NMDA receptor modulator), glucose tolerance and insulin sensitivity, and skin and connective tissue applications. The supplement is sold as the bare amino acid or in combination products targeting specific use cases.

The outcome dimensions covered most heavily are sleep quality (particularly subjective sleep onset and morning alertness, studied at doses around 3 grams before bedtime), schizophrenia and psychotic symptoms as an adjunct to antipsychotics (where glycine is part of the broader NMDA-receptor-modulator literature), insulin sensitivity and glucose tolerance, and oxidative stress markers. Smaller research streams cover skin and joint health (where glycine is a major structural component of collagen) and ischemic injury models in preclinical research.

Demographically, the schizophrenia literature concentrates on adults on stable antipsychotic regimens; the sleep literature is mostly in healthy adults with self-reported sleep difficulties; the metabolic literature is in adults with type 2 diabetes or metabolic syndrome. The unusually broad mechanism set makes glycine difficult to characterize as a single-purpose supplement, which is one of the field's recurring methodological challenges - the same dose may produce changes across multiple systems that are studied separately and rarely measured together.

Glycine is generally well-tolerated at supplemental doses. The most commonly reported adverse effects, mainly at higher doses, are mild gastrointestinal discomfort, nausea, and stomach upset. No tolerable upper limit has been established. Drug interactions are limited; a specific interaction has been reported with clozapine (an antipsychotic) where glycine may reduce its efficacy in some clinical reports. Glycine has been used safely at very high pharmacological doses (15-60 g/day) in some psychiatric trials, but those are clinical research contexts rather than consumer supplementation. People on clozapine specifically should not supplement without medical supervision, and safety in pregnancy and breastfeeding is not established.

This summary is informational and not medical advice. Consult a clinician before starting or changing any supplement, especially if you take prescription medications.